In previous studies, everolimus, another mTOR inhibitor, was found not to be effective in improving the overall survival of advanced GC patients [41, 42], although Park et al. reported that the drug was satisfactory in a diffuse-type GC patient with PIK3CA mutation [43]. Here, PIK3CA is linked to gastric cancer.